Gilead CEO Daniel O’Day has stated that there will be enough global supply of remdesivir available by the end of October. Patients with COVID-19 recover five days quicker when taking the treatment, according to a study published in The New England Journal of Medicine. (CNBC)

Eli Lilly and The Bill & Melinda Gates Foundation have joined together to supply Lilly’s experimental antibody treatments for COVID-19 to low- and middle-income countries. The deal commits Lilly to make its antibody therapies available to lower-income companies before April 2021. (Business Insider)

A city in China plans to test more than 9 million citizens after nine new cases were found. The outbreak in Qingdao marks the first reported virus transmission in China in two months. (AP News)

Most people with Type 1 diabetes don’t seem to be at increased risk of dying or being hospitalized from COVID-19, according to studies published in Diabetes Care. Though the risk of death from the coronavirus is higher overall for Type 1 diabetes, it’s mostly limited to people over 50 with hemoglobin A1c levels above 10% who have had diabetes for a long time. (Medscape)

MM+M is hosting its first Media Summit, an event that will bring together A-list organizations and individuals from all parts of the health-media spectrum. Join us virtually on November 12, 2020. (MM+M)